References
- Huang SM , TempleR . Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice . Clin. Pharmacol. Ther.84 ( 3 ), 287 – 294 ( 2008 ).
- Danhof M , De LangeEC , Della PasquaOE , PloegerBA , VoskuylRA . Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research . Trends Pharmacol. Sci.29 ( 4 ), 186 – 191 ( 2008 ).
- Huang SM , BhattaramA , MehrotraN , WangY . Is this the dose for you? The role of modeling . Clin. Pharmacol. Ther.93 ( 2 ), 159 – 162 ( 2013 ).
- Dubovsky SL . The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression . Expert Opin. Drug Metab. Toxicol.11 ( 3 ), 369 – 379 ( 2015 ).
- Katsanos KH , PapadakisKA . Pharmacogenetics of inflammatory bowel disease . Pharmacogenomics15 ( 16 ), 2049 – 2062 ( 2014 ).
- Talameh JA , KitzmillerJP . Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants . J. Pharmacogenomics Pharmacoproteomics5 ( 2 ), pii: 128 ( 2014 ).
- Rollason V , SamerCF , DaaliY , DesmeulesJA . Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti- inflammatory drugs: a review . Curr. Drug Metab.15 ( 3 ), 326 – 343 ( 2014 ).
- FDA . %www.fda.gov/Drugs/ScienceResearch/%20ResearchAreas/Pharmacogenetics/ucm083378.htm .
- CPIC . www.pharmgkb.org/page/cpic .
- Lesko LJ , ZinehI . DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA . Pharmacogenomics11 ( 4 ), 507 – 512 ( 2010 ).
- Shaw PM , ZinehI . Generating and weighing evidence in drug development and regulatory decision making: 5th US FDA-DIA workshop on pharmacogenomics . Pharmacogenomics11 ( 12 ), 1629 – 1635 ( 2010 ).
- FDA . Pharmacogenomic Data Submissions . www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf .
- FDA . Pharmacogenomic Biomarkers in Drug Labeling . www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm .
- Conrado DJ , RogersHL , ZinehI , PacanowskiMA . Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels . Pharmacogenomics14 ( 2 ), 215 – 223 ( 2013 ).
- Maliepaard M , NofzigerC , PapalucaMet al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective . Nat. Rev. Drug Discov.12 ( 2 ), 103 – 115 ( 2013 ).
- EMA . Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products . www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500121954.pdf .
- I-Pwg . i-pwg.org .
- Williams JA , AnderssonT , AnderssonTBet al. PhRMA white paper on ADME pharmacogenomics . J. Clin. Pharmacol.48 ( 7 ), 849 – 889 ( 2008 ).
- Franc MA , WarnerAW , CohenN , ShawPM , GroenenP , SnapirA . Current practices for DNA sample collection and storage in the pharmaceutical industry, and potential areas for harmonization: perspective of the I-PWG . Clin. Pharmacol. Ther.89 ( 4 ), 546 – 553 ( 2011 ).
- PharmaADME . www.PharmaADME.org .
- Caudle KE , KleinTE , HoffmanJMet al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process . Curr. Drug Metab.15 ( 2 ), 209 – 217 ( 2014 ).
- Zanger UM , KleinK , ThomasMet al. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes . Clin. Pharmacol. Ther.95 ( 3 ), 258 – 261 ( 2014 ).
- Niemi M . Transporter pharmacogenetics and statin toxicity . Clin. Pharmacol. Ther.87 ( 1 ), 130 – 133 ( 2010 ).
- Dietrich CG , GeierA . Effect of drug transporter pharmacogenetics on cholestasis . Expert Opin. Drug Metab. Toxicol.10 ( 11 ), 1533 – 1551 ( 2014 ).
- Bruhn O , CascorbiI . Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance . Expert Opin. Drug Metab. Toxicol.10 ( 10 ), 1337 – 1354 ( 2014 ).
- Wang D , GuoY , WrightonSA , CookeGE , SadeeW . Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs . Pharmacogenomics J.11 ( 4 ), 274 – 286 ( 2011 ).
- Thomas M , BurkO , KlumppBet al. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARalpha) . Mol. Pharmacol.83 ( 3 ), 709 – 718 ( 2013 ).
- Rieger JK , KleinK , WinterS , ZangerUM . Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association with gene expression . Drug Metab. Dispos.41 ( 10 ), 1752 – 1762 ( 2013 ).
- FDA . Anticipated Details of the Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories . www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm416684.pdf .
- Karolinska . The Human Cytochrome P450 (CYP) Allele Nomenclature Database ( 2014 ). www.cypalleles.ki.se/ .
- Pharmaaddme . Pharmaaddme.org .
- Pharmgkb . =www.pharmgkb.org/search/browseVip.action?browseKey=vipGenes .
- FDA . Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations . www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf .
- Niwa T , MurayamaN , EmotoC , YamazakiH . Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5 . Curr. Drug Metab.9 ( 1 ), 20 – 33 ( 2008 ).
- Verhaeghe T . Bioanalytical outsourcing strategy at Janssen Research and Development . Bioanalysis6 ( 10 ), 1321 – 1327 ( 2014 ).
- Oliver GR , HartSN , KleeEW . Bioinformatics for clinical next generation sequencing . Clin. Chem.61 ( 1 ), 124 – 135 ( 2015 ).
- FDA . Optimizing FDA’s regulatory oversight of next generation sequencing diagnostic tests – preliminary discussion paper . www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM427869.pdf .
- Swen JJ , NijenhuisM , De BoerAet al. Pharmacogenetics: from bench to byte – an update of guidelines . Clin. Pharmacol. Ther.89 ( 5 ), 662 – 673 ( 2011 ).
- Penner N , XuL , PrakashC . Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?Chem. Res. Toxicol.25 ( 3 ), 513 – 531 ( 2012 ).